• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用深度学习进行多囊肾和肝体积的专家级分割。

Expert-level segmentation using deep learning for volumetry of polycystic kidney and liver.

机构信息

Synergy A.I. Co.Ltd., Chuncheon, Korea.

Department of Urology, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.

出版信息

Investig Clin Urol. 2020 Nov;61(6):555-564. doi: 10.4111/icu.20200086.

DOI:10.4111/icu.20200086
PMID:33135401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7606119/
Abstract

PURPOSE

Volumetry is used in polycystic kidney and liver diseases (PKLDs), including autosomal dominant polycystic kidney disease (ADPKD), to assess disease progression and drug efficiency. However, since no rapid and accurate method for volumetry has been developed, volumetry has not yet been established in clinical practice, hindering the development of therapies for PKLD. This study presents an artificial intelligence (AI)-based volumetry method for PKLD.

MATERIALS AND METHODS

The performance of AI was first evaluated in comparison with ground-truth (GT). We trained a V-net-based convolutional neural network on 175 ADPKD computed tomography (CT) segmentations, which served as the GT and were agreed upon by 3 experts using images from 214 patients analyzed with volumetry. The dice similarity coefficient (DSC), interobserver correlation coefficient (ICC), and Bland-Altman plots of 39 GT and AI segmentations in the validation set were compared. Next, the performance of AI on the segmentation of 50 random CT images was compared with that of 11 PKLD specialists based on the resulting DSC and ICC.

RESULTS

The DSC and ICC of the AI were 0.961 and 0.999729, respectively. The error rate was within 3% for approximately 95% of the CT scans (error<1%, 46.2%; 1%≤error<3%, 48.7%). Compared with the specialists, AI showed moderate performance. Furthermore, an outlier in our results confirmed that even PKLD specialists can make mistakes in volumetry.

CONCLUSIONS

PKLD volumetry using AI was fast and accurate. AI performed comparably to human specialists, suggesting its use may be practical in clinical settings.

摘要

目的

体积测量用于多囊肾病和肝病(PKLDs),包括常染色体显性多囊肾病(ADPKD),以评估疾病进展和药物疗效。然而,由于尚未开发出快速准确的体积测量方法,因此体积测量尚未在临床实践中得到建立,这阻碍了 PKLD 治疗方法的发展。本研究提出了一种用于 PKLD 的基于人工智能(AI)的体积测量方法。

材料和方法

首先评估 AI 的性能与真实值(GT)进行比较。我们在 175 个 ADPKD CT 分割上训练了一个基于 V-net 的卷积神经网络,这些分割用作 GT,并由 3 位专家使用来自 214 位患者的图像进行体积测量来达成一致。比较了验证集中 39 个 GT 和 AI 分割的骰子相似系数(DSC)、观察者间相关系数(ICC)和 Bland-Altman 图。接下来,根据所得的 DSC 和 ICC,比较了 AI 在 50 张随机 CT 图像分割上的性能与 11 位 PKLD 专家的性能。

结果

AI 的 DSC 和 ICC 分别为 0.961 和 0.999729。对于大约 95%的 CT 扫描,误差率在 3%以内(误差<1%,46.2%;1%≤误差<3%,48.7%)。与专家相比,AI 表现出中等性能。此外,我们结果中的一个异常值证实,即使是 PKLD 专家也可能在体积测量中出错。

结论

使用 AI 的 PKLD 体积测量快速准确。AI 的性能与人类专家相当,表明其在临床环境中的应用可能是实用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/9b8e52a76960/icu-61-555-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/60a211f266c5/icu-61-555-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/9a058fb305c9/icu-61-555-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/bd8746797f72/icu-61-555-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/df1ac9411de2/icu-61-555-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/9b8e52a76960/icu-61-555-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/60a211f266c5/icu-61-555-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/9a058fb305c9/icu-61-555-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/bd8746797f72/icu-61-555-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/df1ac9411de2/icu-61-555-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6363/7606119/9b8e52a76960/icu-61-555-g005.jpg

相似文献

1
Expert-level segmentation using deep learning for volumetry of polycystic kidney and liver.使用深度学习进行多囊肾和肝体积的专家级分割。
Investig Clin Urol. 2020 Nov;61(6):555-564. doi: 10.4111/icu.20200086.
2
Polycystic liver: automatic segmentation using deep learning on CT is faster and as accurate compared to manual segmentation.多囊性肝病:相较于手动分割,利用 CT 上的深度学习进行自动分割更快且同样准确。
Eur Radiol. 2022 Jul;32(7):4780-4790. doi: 10.1007/s00330-022-08549-1. Epub 2022 Feb 10.
3
Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease.人工智能决策支持系统在常染色体显性多囊肾病托伐普坦处方中的可行性。
Investig Clin Urol. 2023 May;64(3):255-264. doi: 10.4111/icu.20220411.
4
A Deep Learning Approach for Automated Segmentation of Kidneys and Exophytic Cysts in Individuals with Autosomal Dominant Polycystic Kidney Disease.深度学习方法自动分割常染色体显性多囊肾病患者的肾脏和外生性囊肿。
J Am Soc Nephrol. 2022 Aug;33(8):1581-1589. doi: 10.1681/ASN.2021111400. Epub 2022 Jun 29.
5
Automated Kidney and Liver Segmentation in MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Study.多囊肾病患者磁共振图像中肾和肝的自动分割:一项多中心研究。
Kidney360. 2022 Dec 29;3(12):2048-2058. doi: 10.34067/KID.0003192022.
6
IRIS-Intelligent Rapid Interactive Segmentation for Measuring Liver Cyst Volumes in Autosomal Dominant Polycystic Kidney Disease.IRIS-智能快速交互式分割法用于测量常染色体显性多囊肾病中的肝囊肿体积。
Tomography. 2022 Feb 9;8(1):447-456. doi: 10.3390/tomography8010037.
7
Deep learning-based automated kidney and cyst segmentation of autosomal dominant polycystic kidney disease using single vs. multi-institutional data.基于深度学习的常染色体显性多囊肾病的自动肾和囊肿分割:使用单中心与多中心数据。
Clin Imaging. 2024 Feb;106:110068. doi: 10.1016/j.clinimag.2023.110068. Epub 2023 Dec 12.
8
Two-stage deep learning model for fully automated pancreas segmentation on computed tomography: Comparison with intra-reader and inter-reader reliability at full and reduced radiation dose on an external dataset.基于 CT 的全自动胰腺分割的两阶段深度学习模型:在外部数据集上比较全剂量和低剂量下的同读者和异读者可靠性。
Med Phys. 2021 May;48(5):2468-2481. doi: 10.1002/mp.14782. Epub 2021 Mar 16.
9
Deep Learning Algorithm for Automated Segmentation and Volume Measurement of the Liver and Spleen Using Portal Venous Phase Computed Tomography Images.基于门静脉期 CT 图像的肝脏和脾脏自动分割与体积测量深度学习算法。
Korean J Radiol. 2020 Aug;21(8):987-997. doi: 10.3348/kjr.2020.0237.
10
Validation of a fully automated liver segmentation algorithm using multi-scale deep reinforcement learning and comparison versus manual segmentation.使用多尺度深度强化学习的全自动肝脏分割算法的验证及与手动分割的比较
Eur J Radiol. 2020 May;126:108918. doi: 10.1016/j.ejrad.2020.108918. Epub 2020 Mar 5.

引用本文的文献

1
The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study.基线总肾体积增长率在预测托伐普坦对常染色体显性多囊肾病患者疗效中的作用:一项可行性研究
J Clin Med. 2025 Feb 21;14(5):1449. doi: 10.3390/jcm14051449.
2
Segmentation of ADPKD Computed Tomography Images with Deep Learning Approach for Predicting Total Kidney Volume.基于深度学习方法的常染色体显性多囊肾病计算机断层扫描图像分割以预测总肾体积
Biomedicines. 2025 Jan 22;13(2):263. doi: 10.3390/biomedicines13020263.
3
Multiscale and multimodal evaluation of autosomal dominant polycystic kidney disease development.

本文引用的文献

1
Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).一项随机对照试验,以确定规定饮水量预防常染色体显性多囊肾病导致肾衰竭的疗效和安全性(PREVENT-ADPKD)。
BMJ Open. 2018 Jan 21;8(1):e018794. doi: 10.1136/bmjopen-2017-018794.
2
Fully Automated Segmentation of Polycystic Kidneys From Noncontrast Computed Tomography: A Feasibility Study and Preliminary Results.多囊肾的全自动 CT 分割:一项可行性研究及初步结果。
Acad Radiol. 2018 Jul;25(7):850-855. doi: 10.1016/j.acra.2017.11.015. Epub 2018 Jan 10.
3
常染色体显性多囊肾病发展的多尺度多模态评估。
Commun Biol. 2024 Sep 19;7(1):1183. doi: 10.1038/s42003-024-06868-1.
4
Comparison of Vision Transformers and Convolutional Neural Networks in Medical Image Analysis: A Systematic Review.医学图像分析中视觉转换器与卷积神经网络的比较:系统评价。
J Med Syst. 2024 Sep 12;48(1):84. doi: 10.1007/s10916-024-02105-8.
5
AI models for automated segmentation of engineered polycystic kidney tubules.用于自动分割工程化多囊肾病管腔的 AI 模型。
Sci Rep. 2024 Feb 3;14(1):2847. doi: 10.1038/s41598-024-52677-1.
6
CT-based radiomics: predicting early outcomes after percutaneous transluminal renal angioplasty in patients with severe atherosclerotic renal artery stenosis.基于CT的放射组学:预测重度动脉粥样硬化性肾动脉狭窄患者经皮腔内肾血管成形术后的早期预后
Vis Comput Ind Biomed Art. 2024 Jan 12;7(1):1. doi: 10.1186/s42492-023-00152-5.
7
Artificial Intelligence-powered automatic volume calculation in medical images - available tools, performance and challenges for nuclear medicine.人工智能助力医学图像自动容积计算——核医学可用工具、性能与挑战。
Nuklearmedizin. 2023 Dec;62(6):343-353. doi: 10.1055/a-2200-2145. Epub 2023 Nov 23.
8
Non-contrast low-dose CT can be used for volumetry of ADPKD.非增强低剂量 CT 可用于 ADPKD 的容量测量。
BMC Nephrol. 2023 Oct 26;24(1):317. doi: 10.1186/s12882-023-03359-z.
9
Test Retest Reproducibility of Organ Volume Measurements in ADPKD Using 3D Multimodality Deep Learning.使用 3D 多模态深度学习评估 ADPKD 中器官体积测量的测试-重测可重复性。
Acad Radiol. 2024 Mar;31(3):889-899. doi: 10.1016/j.acra.2023.09.009. Epub 2023 Oct 3.
10
Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease.人工智能决策支持系统在常染色体显性多囊肾病托伐普坦处方中的可行性。
Investig Clin Urol. 2023 May;64(3):255-264. doi: 10.4111/icu.20220411.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
4
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.用于多囊肾全自动分割的人工多观察者深度神经网络的性能
J Digit Imaging. 2017 Aug;30(4):442-448. doi: 10.1007/s10278-017-9978-1.
5
Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease.基于深度学习的肾脏自动分割在常染色体显性多囊肾病中全肾体积定量分析中的应用。
Sci Rep. 2017 May 17;7(1):2049. doi: 10.1038/s41598-017-01779-0.
6
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.多中心、开放标签、扩展试验,旨在评估托伐普坦早期治疗与延迟治疗对常染色体显性多囊肾病的长期疗效和安全性:TEMPO 4:4试验
Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079.
7
Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease.对于常染色体显性多囊肾病门诊患者,全肾和肝脏体积是营养不良的主要危险因素。
BMC Nephrol. 2017 Jan 14;18(1):22. doi: 10.1186/s12882-016-0434-0.
8
Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.常染色体显性多囊肾病患者腹部MR图像中肝脏及肝囊肿的自动分割
Phys Med Biol. 2016 Nov 21;61(22):7864-7880. doi: 10.1088/0031-9155/61/22/7864. Epub 2016 Oct 25.
9
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.西罗莫司对常染色体显性遗传性多囊肾病及慢性肾脏病3b-4期患者疾病进展的影响
Clin J Am Soc Nephrol. 2016 May 6;11(5):785-794. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22.
10
Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病中肿块效应的临床关联
PLoS One. 2015 Dec 7;10(12):e0144526. doi: 10.1371/journal.pone.0144526. eCollection 2015.